Back to Search
Start Over
Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial
- Source :
- SKIN The Journal of Cutaneous Medicine. 6:s47
- Publication Year :
- 2022
- Publisher :
- National Society for Cutaneous Medicine, 2022.
-
Abstract
- N/A
- Subjects :
- Dermatology
Subjects
Details
- ISSN :
- 25741624
- Volume :
- 6
- Database :
- OpenAIRE
- Journal :
- SKIN The Journal of Cutaneous Medicine
- Accession number :
- edsair.doi...........9d1f6d2a250a999eb3fe96a22646d151
- Full Text :
- https://doi.org/10.25251/skin.6.supp.47